Shanghai Pharmaceuticals Holding Co., Ltd (02607.HK) Latest Company News

Aug 27, 2026, 11:08 UTC
Shanghai Pharmaceuticals declared an interim dividend of RMB 0.10 per share for the six months ended June 2026, down from RMB 0.12 per share in the prior year.
Source:
- aastocks.com
Aug 27, 2026, 09:19 UTC
Shanghai Pharmaceuticals reported a net profit of 3.50 billion yuan for the first half of 2026.
Source:
Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.
Source:
- finance.sina.cn
Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharma Holding will publicly list for transfer its 51% stake in subsidiary Shanghai Shangyao Xinte Dong'an Pharmacy Co., Ltd. via a property rights exchange, with a proposed minimum price of 179 million yuan.
Source:
- finance.sina.cn
- tmtpost.com
Aug 18, 2026, 00:17 UTC
Hangzhou Huqingyutang Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, started construction of a production workshop with an annual capacity of 2.2 billion capsules on August 15, 2026.
Source:
- finance.sina.cn
Aug 3, 2026, 07:33 UTC
Shanghai Pharmaceuticals' subsidiary SPH Sine received a drug registration certificate from the National Medical Products Administration for omeprazole and sodium bicarbonate dry suspension (I), approving its production.
Source:
- finance.sina.cn
- aastocks.com
Jul 30, 2026, 07:51 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhonghua received product licenses from Health Canada for three Longhu products: classic and strong versions of cooling balm and Longhu rollerball essential balm.
Source:
- finance.sina.cn
Jul 30, 2026, 07:51 UTC
Shanghai Pharmaceuticals' subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from the National Medical Products Administration approving the production of Rosuvastatin/Ezetimibe Tablets (I).
Source:
- finance.sina.cn
- finance.sina.cn
Jul 24, 2026, 09:58 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. signed a limited partnership agreement to invest 300 million yuan as a limited partner in the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership.
Source:
Jul 20, 2026, 07:52 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhongyaosuo received a drug clinical trial approval notice from the National Medical Products Administration for Qingrun Yangmu Granules to treat dry eye.
Source:
- finance.sina.cn
Jul 17, 2026, 12:09 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. plans to list and transfer its 41% stake in subsidiary Shangyao Yiyi Pharmaceutical (Shanghai) Co., Ltd. via a public auction at a property rights exchange, with a base price of 330 million yuan.
Source:
- finance.sina.cn

02607.HK

Shanghai Pharmaceuticals declared an interim dividend of RMB 0.10 per share for the six months ended June 2026, down from RMB 0.12 per share in the prior year.

Shanghai Pharmaceuticals reported a net profit of 3.50 billion yuan for the first half of 2026.

Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.

Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharma Holding will publicly list for transfer its 51% stake in subsidiary Shanghai Shangyao Xinte Dong'an Pharmacy Co., Ltd. via a property rights exchange, with a proposed minimum price of 179 million yuan.

Hangzhou Huqingyutang Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, started construction of a production workshop with an annual capacity of 2.2 billion capsules on August 15, 2026.

Shanghai Pharmaceuticals' subsidiary SPH Sine received a drug registration certificate from the National Medical Products Administration for omeprazole and sodium bicarbonate dry suspension (I), approving its production.

Shanghai Pharmaceuticals' subsidiary Shangyao Zhonghua received product licenses from Health Canada for three Longhu products: classic and strong versions of cooling balm and Longhu rollerball essential balm.

Shanghai Pharmaceuticals' subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from the National Medical Products Administration approving the production of Rosuvastatin/Ezetimibe Tablets (I).

Shanghai Pharmaceuticals Holding Co., Ltd. signed a limited partnership agreement to invest 300 million yuan as a limited partner in the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership.

Shanghai Pharmaceuticals' subsidiary Shangyao Zhongyaosuo received a drug clinical trial approval notice from the National Medical Products Administration for Qingrun Yangmu Granules to treat dry eye.

Shanghai Pharmaceuticals Holding Co., Ltd. plans to list and transfer its 41% stake in subsidiary Shangyao Yiyi Pharmaceutical (Shanghai) Co., Ltd. via a public auction at a property rights exchange, with a base price of 330 million yuan.